BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX: RGN) (www.regenerx.com) reported today that a study published in the advanced online edition of the journal Nature supported and elaborated Tß4’s significant effects in the damaged hearts of mice and highlighted its therapeutic potential for the treatment of heart attacks and heart failure in humans.
